N/A
Completed N=33
Assessing Electronic Cigarette Nicotine Flux
Source: ClinicalTrials.gov NCT04378907 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: Plasma Nicotine Concentration — 2.00; 1.92; 1.64; 1.62 mg/ml
Summary
The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Nicotine Concentration |
2.00; 1.92; 1.64; 1.62; 1.93; 4.75 | — |
| PRIMARY Cigarette/ECIG Challenge Paradigm |
7.74; 10.18; 10.51; 11.64 | — |
| SECONDARY Puff Volume |
424.46; 425.48; 363.21; 328.52; 400.87; 372.31 | — |
| SECONDARY Puff Duration |
2.31; 2.32; 2.16; 2.01; 2.26; 2.08 | — |
Eligibility Criteria
Inclusion Criteria
- healthy (determined by self-report)
- between the ages of 18-55
- willing to provide informed consent
- able to attend the lab and abstain from tobacco/nicotine as required and must agree to use designated products according to study protocol
Exclusion Criteria
- Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.
Data sourced from ClinicalTrials.gov (NCT04378907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.